{"id":255494,"date":"2024-02-07T00:00:00","date_gmt":"2024-02-07T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0017-2024-biopharma-alzheimers-disease-special-topics-special\/"},"modified":"2026-03-31T10:31:03","modified_gmt":"2026-03-31T10:31:03","slug":"sptocg0017-2024-biopharma-alzheimers-disease-special-topics-special-topics-caregiver-perspectives-on-diagnostics-and","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0017-2024-biopharma-alzheimers-disease-special-topics-special-topics-caregiver-perspectives-on-diagnostics-and\/","title":{"rendered":"Alzheimer&#8217;s Disease &#8211; Special Topics &#8211; Special Topics: Caregiver Perspectives on Diagnostics and Leqembi in the Treatment of Alzheimer\u2019s Disease (US)"},"content":{"rendered":"<p>Eisai \/ Biogen\u2019s Leqembi (lecanemab) gained accelerated and full <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-<abbr title=\"Alzheimer's disease\">AD<\/abbr> trial. With the U.S. <abbr title=\"Centers for Medicare &#038; Medicaid Services\">CMS<\/abbr> covering the drug in line with its label and broadening reimbursement of <abbr title=\"positron emission tomography\">PET<\/abbr> scans used to establish diagnoses and determine treatment eligibility, Leqembi is poised to capitalize on the unfulfilled potential for an <abbr title=\"Alzheimer's disease\">AD<\/abbr> <abbr title=\"disease-modifying therapy\">DMT<\/abbr>. However, logistic hurdles on the path to diagnosis and treatment initiation must be overcome to unlock the full potential of a <abbr title=\"disease-modifying therapy\">DMT<\/abbr> in the <abbr title=\"Alzheimer's disease\">AD<\/abbr> market. This survey-based report assesses U.S. caregivers\u2019 experiences with their patient\u2019s path to diagnosis of <abbr title=\"Alzheimer's disease\">AD<\/abbr>, unspecified dementia, or unspecified\u00a0<abbr title=\"mild cognitive impairment\">MCI<\/abbr>. It also explores\u00a0caregivers\u2019 awareness of, familiarity with, and perceptions of Leqembi, including their willingness to seek treatment or drive further diagnostic clarity. With additional <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s expected to enter the market in 2024, the analysis will also shed light on the drivers and constraints influencing the use of Leqembi and identify opportunities for current and future developers to support <abbr title=\"disease-modifying therapy\">DMT<\/abbr> uptake.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the drivers of \/ obstacles to diagnosis of <abbr title=\"Alzheimer's disease\">AD<\/abbr> or related disorders according to caregivers?<\/li>\n<li>What is the level of awareness of and familiarity with Leqembi among U.S. caregivers in the first year after launch?<\/li>\n<li>How do U.S. caregivers perceive Leqembi as a treatment for <abbr title=\"Alzheimer's disease\">AD<\/abbr>, and how willing are they and their patients to seek treatment?<\/li>\n<li>Is the approval of Leqembi driving caregivers of unspecified dementia or <abbr title=\"mild cognitive impairment\">MCI<\/abbr> patients to seek a more granular diagnosis?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Clarivate\u2019s Special Topics reports use quantitative and\/or qualitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report will help developers in shaping their market strategies, identifying potential areas for differentiation, and caregivers\u2019 receptivity.<\/p>\n","protected":false},"template":"","class_list":["post-255494","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-therapy-areas-neurology","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/255494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/255494\/revisions"}],"predecessor-version":[{"id":575989,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/255494\/revisions\/575989"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=255494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}